Skip to main content
Top
Published in: Lung 2/2015

01-04-2015

Continuous Positive Airways Pressure and Uvulopalatopharyngoplasty Improves Pulmonary Hypertension in Patients with Obstructive Sleep Apnoea

Authors: Maurizio Marvisi, Maurizio Giuseppe Vento, Laura Balzarini, Chiara Mancini, Chiara Marvisi

Published in: Lung | Issue 2/2015

Login to get access

Abstract

Objective

Data are sparse regarding the prevalence of pulmonary hypertension (PH) in obstructive sleep apnoea (OSA) patients without COPD and clinically manifest cardiac diseases and the role of continuous positive airway pressure (CPAP) and Uvulopalatopharyngoplasty (UPPP) in normalizing this parameter.

Patients/Methods

We studied 75 consecutive OSA patients, 55 of them men, using transthoracic echocardiography. A mild PH [pulmonary artery pressure (PAPs) 38.2 ± 6.8] was found in 25 subjects (prevalence 33 %). These patients were divided into two groups: group 1A (n = 17), those treated with CPAP, and group 1B (n = 8), those who have the indication for a UPPP. We scheduled a follow-up at 3, 6 and 9 months. During follow-up, we performed echocardiography, measurement of anthropometric parameters (BMI, neck and waist–hip circumference), and of biochemical parameters (uric acid, fasting glucose, cholesterol, triglycerides) and blood pressure.

Results

Patients with PH had a higher BMI: 32 ± 6 versus 29 ± 4 (p < 0.001) and NC: 39.8 ± 4.76 versus 37.14 ± 3.49 (p = 0.003), were predominantly men (72 %) and older: 64 ± 20 versus 55 ± 16 (p = 0.025) and had a significantly higher value of uric acid: 7.91 ± 2.35 versus 6.56 ± 1.31 (p = 0.003). We found a positive correlation between PH and BMI (r = 0.456; p < 0.001) and between uric acidic and PH (r = 0.636; p < 0.001). PAPs significantly changed, from 39.8 ± 4.1 to 27.1 ± 4, to 25.2 ± 3.1 and to 22.2 ± 3 mmHg (CI 95 %; 15.09–20.11; p < 0.001) in group 1A and from 39.5 ± 5.1 to 23.4 ± 3.2, to 23.0 ± 3.1 and to 21.9 ± 2.9 mmHg (CI 95 %; 13.15–22.05; p < 0.001) in group 1B (difference between the groups p = 0.12).

Conclusions

PH was frequent in OSA patients and normalized after 6 months with both CPAP and UPPP. A similar trend was noted in diastolic blood pressure.
Literature
1.
go back to reference Atwood CW, Mc Crory D, Garcia JGN et al (2004) Pulmonary artery hypertension and sleep disordered breathing. ACCP evidence based clinical practice guidelines. Chest 126:72S–77SCrossRefPubMed Atwood CW, Mc Crory D, Garcia JGN et al (2004) Pulmonary artery hypertension and sleep disordered breathing. ACCP evidence based clinical practice guidelines. Chest 126:72S–77SCrossRefPubMed
2.
go back to reference Minai OA, Ricaurte B, Kaw R et al (2009) Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 104:1300–1306CrossRefPubMed Minai OA, Ricaurte B, Kaw R et al (2009) Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 104:1300–1306CrossRefPubMed
3.
go back to reference Naeije R, Torbicki A (1995) More on the non invasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 8:1445–1449PubMed Naeije R, Torbicki A (1995) More on the non invasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 8:1445–1449PubMed
4.
go back to reference Sajkov D, Wang T, Saunders NA et al (2002) Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 165:152–158CrossRefPubMed Sajkov D, Wang T, Saunders NA et al (2002) Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 165:152–158CrossRefPubMed
6.
go back to reference Sun X, Luo J, Xiao J (2014) Continuous positive airway pressure is associated with a decrease in pulmonary artery hypertension in patients with OSA: a meta-analysis. Respirology 19:670–674CrossRefPubMed Sun X, Luo J, Xiao J (2014) Continuous positive airway pressure is associated with a decrease in pulmonary artery hypertension in patients with OSA: a meta-analysis. Respirology 19:670–674CrossRefPubMed
7.
go back to reference Braga A, Grechi TH, Eckeli A et al (2013) Predictors of UPPP success in the treatment of obstructive sleep apnoea syndrome. Sleep Med 14:1266–1271CrossRefPubMed Braga A, Grechi TH, Eckeli A et al (2013) Predictors of UPPP success in the treatment of obstructive sleep apnoea syndrome. Sleep Med 14:1266–1271CrossRefPubMed
8.
go back to reference Coccagna G, Pollini A, Provini F (2006) Cardiovascular disorders and obstructive sleep apnoea. Clin Exp Hypertens 28:217–224CrossRefPubMed Coccagna G, Pollini A, Provini F (2006) Cardiovascular disorders and obstructive sleep apnoea. Clin Exp Hypertens 28:217–224CrossRefPubMed
10.
go back to reference Alchanatis M, Tourkohoriti G, Kakouros S et al (2001) Daytime pulmonary hypertension in patients with obstructive sleep apnea. The effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration 68:566–572CrossRefPubMed Alchanatis M, Tourkohoriti G, Kakouros S et al (2001) Daytime pulmonary hypertension in patients with obstructive sleep apnea. The effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration 68:566–572CrossRefPubMed
11.
go back to reference Arias MA, Garcia Rio F, Alfonso Fernandez A et al (2006) Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure. A randomized control cross-over study. Eur Heart J 27:1106–1113CrossRefPubMed Arias MA, Garcia Rio F, Alfonso Fernandez A et al (2006) Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure. A randomized control cross-over study. Eur Heart J 27:1106–1113CrossRefPubMed
12.
go back to reference Minic M, Granton JT, Ryan CM (2014) Sleep disordered breathing in group 1 pulmonary arterial hypertension. J Clin Sleep Med 10:277–283PubMedCentralPubMed Minic M, Granton JT, Ryan CM (2014) Sleep disordered breathing in group 1 pulmonary arterial hypertension. J Clin Sleep Med 10:277–283PubMedCentralPubMed
14.
go back to reference Varendh M, Berg S, Andersson M (2012) Long term follow-up of patients operated with UPPP from 1985 to 1991. Respir Med 106:1788–1793CrossRefPubMed Varendh M, Berg S, Andersson M (2012) Long term follow-up of patients operated with UPPP from 1985 to 1991. Respir Med 106:1788–1793CrossRefPubMed
15.
go back to reference Prudon B, Roddy E, Stradling JR et al (2013) Serum urate levels are unchanged with CPAP therapy for OSA: a randomized controlled trial. Sleep Med 14:1419–1421CrossRefPubMed Prudon B, Roddy E, Stradling JR et al (2013) Serum urate levels are unchanged with CPAP therapy for OSA: a randomized controlled trial. Sleep Med 14:1419–1421CrossRefPubMed
16.
go back to reference Kanbay A, Inou H, Solak Y et al (2014) Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. Eur J Intern Med 25:471–476CrossRefPubMed Kanbay A, Inou H, Solak Y et al (2014) Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. Eur J Intern Med 25:471–476CrossRefPubMed
Metadata
Title
Continuous Positive Airways Pressure and Uvulopalatopharyngoplasty Improves Pulmonary Hypertension in Patients with Obstructive Sleep Apnoea
Authors
Maurizio Marvisi
Maurizio Giuseppe Vento
Laura Balzarini
Chiara Mancini
Chiara Marvisi
Publication date
01-04-2015
Publisher
Springer US
Published in
Lung / Issue 2/2015
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-015-9694-x

Other articles of this Issue 2/2015

Lung 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine